Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

Triple positive breast cancers overexpress both the human epidermal growth factor receptor 2 (HER2) oncogene and the hormonal receptors (HR) to estrogen and progesterone. These cancers represent a unique therapeutic challenge because of a bidirectional cross-talk between the estrogen receptor alpha...

Descripción completa

Detalles Bibliográficos
Autores principales: Schedin, Troy B., Borges, Virginia F., Shagisultanova, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029445/
https://www.ncbi.nlm.nih.gov/pubmed/30018827
http://dx.doi.org/10.1155/2018/7835095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029445/
https://www.ncbi.nlm.nih.gov/pubmed/30018827
http://dx.doi.org/10.1155/2018/7835095

Ejemplares similares